Literature DB >> 8750282

Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis.

J A Vazquez1, T Lundstrom, L Dembry, P Chandrasekar, D Boikov, M B Parri, M J Zervos.   

Abstract

Candida guilliermondii is rarely isolated from humans. We describe a case of disseminated C. guilliermondii with associated purulent pericarditis, despite high-dose amphotericin B (AmB), in a 19-year-old female with aplastic anemia who underwent BMT. In vitro susceptibility studies of the 13 clinical isolates, two control strains and one environmental isolate revealed a minimum inhibitory concentration (MIC) range of (0.19-1.56 micrograms/ml) for AmB and (1.25-10 micrograms/ml) for fluconazole. Pulsed-field gradient gel electrophoresis was performed to evaluate possible similarities between strains. This case is significant for several reasons, the high degree and prolonged duration of fungemia despite high-dose AmB and concomitant flucytosine, the change in in vitro susceptibility during therapy, the initial misidentification of the yeast isolate, and the invasiveness of the organism. The poor response to therapy may have been due to the severe and sustained neutropenia and the high MICs of C. guilliermondii to AmB.

Entities:  

Mesh:

Year:  1995        PMID: 8750282

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Candida guilliermondii fungemia in patients with hematologic malignancies.

Authors:  Corrado Girmenia; Giampaolo Pizzarelli; Francesco Cristini; Francesco Barchiesi; Elisabetta Spreghini; Giorgio Scalise; Pietro Martino
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates.

Authors:  P Steffan; J A Vazquez; D Boikov; C Xu; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

5.  High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance.

Authors:  S A Yoon; J A Vazquez; P E Steffan; J D Sobel; R A Akins
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  Catheter-related candidemia caused by Candida lipolytica in a patient receiving allogeneic bone marrow transplantation.

Authors:  Domenico D'Antonio; Ferdinando Romano; Eugenio Pontieri; Giuseppe Fioritoni; Claudia Caracciolo; Stefano Bianchini; Paola Olioso; Tommaso Staniscia; Roberta Sferra; Stefania Boccia; Antonella Vetuschi; Giovanni Federico; Eugenio Gaudio; Giuseppe Carruba
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

Review 8.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Catheter-related candidemia caused by Candida haemulonii in a patient in long-term hospital care.

Authors:  Sunyong Kim; Kwan Soo Ko; Su Yeon Moon; Mi Suk Lee; Mi Young Lee; Jun Seong Son
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

10.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.